Candel Therapeutics appointed Martine Zimmermann to its board, with an option to purchase 64,000 common shares. She will also receive a $40,000 annual board retainer. Her regulatory and quality background is intended to support Candel as it advances toward a planned BLA submission and potential commercial readiness.

Key Highlights

  • Martine Zimmermann will receive a $40,000 annual retainer for board service.
  • The appointment became effective on September 8, 2026, after board approval on September 6, 2026.
  • Zimmermann will receive a $40,000 annual retainer and an option to purchase 64,000 common shares.

Candel Therapeutics, Inc. (NASDAQ: CADL) appointed Martine Zimmermann to its board with an option to purchase 64,000 common shares. The appointment adds regulatory and quality expertise as Candel advances toward a planned Biologics License Application submission and potential commercial readiness.

Zimmermann’s Board Terms and Regulatory Background

The board approved Zimmermann’s appointment on September 6, 2026, and she began serving on September 8, 2026. Zimmermann will receive a $40,000 annual retainer, paid quarterly in arrears and prorated according to the number of days served during the quarter. Her compensation also includes the option grant and the company’s standard indemnification agreement. Earlier positions included senior regulatory Leadership roles at Ipsen Biopharmaceuticals and Alexion Pharma International, where her work covered Drug Development and regulatory engagement across the United States, Europe and Asia-Pacific. The company said she had no arrangement with another person concerning her appointment, no family relationship with a director or executive officer, and no material interest in a transaction requiring disclosure. Candel said more than 1,000 patients have received aglatimagene in clinical trials.